Huber Financial Advisors LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 12.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,456 shares of the company’s stock after selling 365 shares during the period. Huber Financial Advisors LLC’s holdings in Johnson & Johnson were worth $342,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of the business. Evolution Wealth Advisors LLC bought a new position in Johnson & Johnson during the 4th quarter valued at $40,000. Thor Advisors LLC bought a new stake in Johnson & Johnson in the first quarter worth $69,000. Personal Wealth Partners bought a new stake in Johnson & Johnson in the second quarter worth $73,000. Quattro Financial Advisors LLC bought a new stake in Johnson & Johnson in the second quarter worth $92,000. Finally, Financial Gravity Wealth Inc. boosted its holdings in Johnson & Johnson by 36.9% in the second quarter. Financial Gravity Wealth Inc. now owns 809 shares of the company’s stock worth $113,000 after acquiring an additional 218 shares in the last quarter. Hedge funds and other institutional investors own 67.23% of the company’s stock.
Shares of NYSE:JNJ opened at $128.56 on Wednesday. The company has a market cap of $337.10 billion, a P/E ratio of 15.72, a PEG ratio of 2.16 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99. The stock’s fifty day moving average price is $131.66 and its 200-day moving average price is $136.44.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
Several research firms have commented on JNJ. Wells Fargo & Co reissued an “outperform” rating and issued a $157.00 target price (up from $152.00) on shares of Johnson & Johnson in a report on Monday, May 6th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Morgan Stanley reaffirmed an “equal weight” rating and set a $145.00 price target on shares of Johnson & Johnson in a report on Tuesday. Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday. Finally, Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target on the stock. in a report on Thursday, July 18th. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Buy” and a consensus target price of $150.60.
In other news, Director Marillyn A. Hewson acquired 3,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, June 11th. The stock was bought at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the transaction, the director now owns 3,000 shares in the company, valued at $419,040. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.23% of the stock is currently owned by corporate insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: What is a capital gain?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.